Does Aetna Cover Mounjaro?
The verdict
Conditional on most plans
Aetna (CVS Health) covers Mounjaro as a preferred brand on its 2025 CVS Caremark Standard and Advanced Control formularies for type 2 diabetes, with prior authorization (documented A1c of 6.5% or higher and metformin trial). Aetna does not cover Mounjaro for weight loss. CVS Caremark removed Zepbound (the weight-loss tirzepatide) from Standard, Advanced, and Value formularies effective July 1, 2025 — while Mounjaro for diabetes remained at Tier 2 throughout. Zepbound returns as an elected preferred obesity option effective October 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Aetna using your member ID.
Key facts
Mounjaro is a preferred brand (Tier 2) on the 2025 CVS Caremark Standard and Advanced Control formularies for type 2 diabetes. PA requires A1c 6.5% or higher and documented metformin trial.
CVS Caremark Standard Control Formulary, 2025
CVS Caremark removed Zepbound (weight-loss tirzepatide) from Standard, Advanced, and Value formularies effective July 1, 2025. Mounjaro (diabetes tirzepatide) remained on formulary throughout at Tier 2.
CVS Caremark, Formulary Updates, July 2025
Zepbound returns as an elected preferred obesity option for Aetna/CVS Caremark plans beginning October 1, 2026, for plans that opt in — a separate coverage track from Mounjaro.
CVS Caremark, Formulary Announcement, 2026
Medicare vs. commercial coverage
Whether Aetna covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Aetna Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization via CVS Caremark. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2-3 months and pay $0 for the rest of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicare Advantage beneficiaries.
Commercial / Employer
Group & marketplace plans
Aetna commercial and employer-sponsored plans: Mounjaro is a preferred brand on the 2025 CVS Caremark Standard and Advanced Control formularies for type 2 diabetes, with prior authorization (A1c 6.5% or higher, documented metformin trial). Not covered for off-label weight loss. The CVS Caremark Zepbound removal is the sharpest on/off-label illustration in the cluster: CVS removed Zepbound from Standard, Advanced, and Value formularies on July 1, 2025 (Wegovy became preferred for obesity); Mounjaro for diabetes continued at Tier 2 throughout. Zepbound returns as an elected preferred obesity option from October 1, 2026. ACA/Individual: limited; Mounjaro covered for T2D with PA. Medicaid (Aetna Better Health): Tier 2, $0 copay with PA for diabetes. Lilly savings card: $25/month with coverage; $499/month without (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
Aetna commercial preferred brand tier cost-share (Tier 2 on Standard/Advanced Control formularies). Commercially insured with Mounjaro coverage may pay as little as $25/month via Lilly savings card. Aetna Better Health (Medicaid): $0 copay with PA. Medicare Part D: 25% coinsurance to $2,100 OOP cap 2026; MFN $245/month mid-2026.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; confirm cost-share on the Aetna drug lookup tool or CVS Caremark formulary. The Lilly savings card expires 12/31/2026 and is not available to Medicare, Medicaid, or government-program beneficiaries.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm preferred-brand placement on the Aetna/CVS Caremark formulary
Visit aetna.com and use the drug lookup for your specific plan. Mounjaro (tirzepatide) is a preferred brand on the CVS Caremark Standard and Advanced Control formularies for type 2 diabetes in 2025. Confirm the current year's tier and whether PA is required on your specific Aetna plan. This is one of the few carriers where a specific tier can be stated — but always verify for your plan year.
- 2
Have your prescriber submit the CVS Caremark prior authorization
Your prescriber needs to document your T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within ~90 days, and prior metformin trial or documented contraindication. These are CVS Caremark's confirmed PA criteria for Mounjaro. The prescriber submits the PA through CVS Caremark's portal; allow up to 72 hours.
- 3
Understand the Zepbound formulary status if you're asking about weight loss
If you want tirzepatide for weight loss (not diabetes), note that the relevant product is Zepbound — not Mounjaro. CVS Caremark removed Zepbound from Standard, Advanced, and Value formularies on July 1, 2025 (Wegovy is the preferred obesity GLP-1). Zepbound returns as an elected preferred obesity option starting October 1, 2026, for plans that opt in. Mounjaro is not a substitute for weight-loss purposes — it is covered only for confirmed T2D.
Options if Aetna won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. Often at a preferred or non-preferred brand tier through CVS Caremark for Aetna plans with PA. Widely available as a T2D alternative.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; lower list price than Mounjaro; may be on a preferred tier ahead of Mounjaro as step therapy.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. Often on preferred tiers for Aetna commercial and Medicare Advantage plans; may be required step therapy before GLP-1 approval.
Wegovy (semaglutide) — weight loss only
FDA-approved for chronic weight management. After CVS Caremark removed Zepbound from its Standard/Advanced formularies on July 1, 2025, Wegovy became the preferred obesity GLP-1 on CVS Caremark formularies. A different drug and coverage pathway from Mounjaro.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and OSA. Removed from CVS Caremark Standard, Advanced, and Value formularies effective July 1, 2025; returns as an elected preferred obesity option from October 1, 2026 for plans that opt in. Entirely separate coverage track from Mounjaro.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Aetna does not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only; the CVS Caremark PA is gated on a T2D diagnosis and A1c — off-label weight-loss requests are denied. For weight loss, the same active ingredient (tirzepatide) is Zepbound — a separate FDA approval. Note that CVS Caremark removed Zepbound from its standard formularies in mid-2025, so a patient with Aetna can have Mounjaro covered for diabetes while Zepbound is simultaneously off-formulary.
Mounjaro and Zepbound are the same molecule (tirzepatide) but different FDA approvals: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and OSA. CVS Caremark's formulary decision in mid-2025 designated Wegovy as the preferred obesity GLP-1 and removed Zepbound from Standard, Advanced, and Value formularies. Mounjaro for diabetes was unaffected — it remained at Tier 2 throughout. This is a direct consequence of on-label vs. off-label FDA distinctions driving coverage decisions.
Aetna uses CVS Caremark's PA process. The documented criteria for Mounjaro are: confirmed T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within approximately 90 days, and a documented trial or failure of metformin (plus often one additional oral agent). Patient must be 18 or older; QL is typically 4 pens per 28 days. These are CVS Caremark-confirmed criteria — Aetna is the cluster's most-specifiable carrier for PA details.
Mounjaro is a preferred brand (Tier 2) on CVS Caremark Standard and Advanced Control formularies. With commercial Aetna coverage, you may pay as little as $25/month via the Lilly savings card. Without coverage on a commercial plan, the card provides $499/month (up to $647/month, 13 fills, expires 12/31/2026). Aetna Better Health Medicaid: $0 copay with PA. Medicare Part D: 25% coinsurance to the $2,100 OOP cap; MFN $245/month starts mid-2026. Card unavailable for Medicare and Medicaid.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. Aetna Medicare covers Mounjaro under standard Part D for T2D, with PA, preferred-brand tier cost-share, and the $2,100 annual OOP cap.
Related Articles
Does Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Mounjaro? 2026 Guide | Curex
BCBS covers Mounjaro for type 2 diabetes with prior authorization — not for weight loss. The weight-loss tirzepatide is Zepbound, with separate coverage.
Read moreDoes Blue Cross Blue Shield of Arizona Cover Mounjaro? | Curex
BCBS of Arizona covers Mounjaro for type 2 diabetes with prior auth — not weight loss. AZ Medicaid covers Wegovy for weight loss, but not Mounjaro.
Read moreDoes Blue Cross Blue Shield of Texas Cover Mounjaro? 2026 | Curex
BCBS of Texas covers Mounjaro for type 2 diabetes with prior auth — not weight loss. The weight-loss tirzepatide is Zepbound, covered separately.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Mounjaro? HCSC 2026 | Curex
BCBS of Illinois (HCSC) covers Mounjaro for type 2 diabetes with PA — not weight loss. IL Medicaid covers T2D but excludes weight-loss GLP-1s.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
Aetna covers Mounjaro for diabetes, not weight loss — and its CVS Caremark formulary dropped the weight-loss twin Zepbound for much of 2025-2026. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Aetna before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.